IGC Pharma has announced the inclusion of a prominent research center in Colombia into its ongoing Phase 2 CALMA clinical trial for Alzheimer’s disease. This addition aims to increase the genetic diversity of trial participants and enhance the robustness of the study’s findings.
The new site, recognized globally for its expertise in genetics and neuroscience, will contribute to the trial’s goal of generating comprehensive data ahead of a planned 2026 milestone. Expanding the trial to Colombia reflects IGC Pharma’s commitment to inclusive research across diverse populations.
**Why this matters**
Broadening the geographic and genetic scope of clinical trials can improve the understanding of Alzheimer’s disease across different populations. Including diverse participants helps ensure that potential treatments are effective for a wider range of patients, supporting the development of more universally applicable therapies.
Source: NewsData